Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-04-24

Clinical Trial Update: Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update on ketamine for severe adolescent major depressive disorder; study terminated with posted results in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ketamine (ketamine)

Snippet

Sponsor: Yale University | Conditions: Major Depressive Disorder | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2023-04-24